Displaying drugs 951 - 975 of 1864 in total
A-dmDT390-bisFv(UCHT1)
A-dmDT390-bisFv(UCHT1) is under investigation in clinical trial NCT02943642 (Safety and Effectiveness of A-dmdt390-bisfv(ucht1) Fusion Protein in Subjects With Mycosis Fungoides).
Investigational
GS-100
GS-100 is an adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression cassette containing the human NGLY1 gene coding sequence
Investigational
Matched Description: … GS-100 is an adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression …
ATA-100
ATA-100 is an adeno-associated virus serotype 9 carrying the human Fukutin-Related protein gene and target sequence of the miR-208a
Investigational
Matched Description: … ATA-100 is an adeno-associated virus serotype 9 carrying the human Fukutin-Related protein gene and target …
JLK-247
JLK-247 is an adeno-associated viral vector serotype 9 (AAV9)-mediated gene replacement therapy for the treatment of Sanfilippo Syndrome Type C or MPS IIIC.
Investigational
Matched Description: … JLK-247 is an adeno-associated viral vector serotype 9 (AAV9)-mediated gene replacement therapy for the …
MDX-210
Investigational
Medical Cannabis
The use of the plant species Cannabis sativa and Cannabis indica, popularly known as marijuana, has gained popularity in recent years for the management of a wide variety of medical conditions as a wave of legalization in North America has changed public and medical opinion on its use. Consequently, an...
Experimental
Investigational
Matched Description: … The primary psychoactive component of Cannabis, delta 9-tetrahydrocannabinol (Δ9-THC), demonstrates its …
Plumbagin
Plumbagin is a compound investigated for its anticancer activity. It has been found that it inactivates the Akt/NF-kB, MMP-9 and VEGF pathways.
Investigational
Matched Description: … It has been found that it inactivates the Akt/NF-kB, MMP-9 and VEGF pathways.[A253102] …
Fenproporex
Fenproporex is an orally active stimulant drug, which was developed in the 1960s. It is used as an appetite suppressant and a treatment for obesity. It is listed as an illicit substance in many countries due to addiction issues and listed as a prohibited substance by the World Anti-Doping Agency....
Experimental
Illicit
Withdrawn
ES-936
Experimental
SBT101
SBT101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1) gene.
Investigational
Matched Description: … SBT101 is a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector …
CPG 10101
CPG 10101 is a synthetic oligodeoxynucleotide (ODN) in clinical trials. It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV.
Investigational
Matched Description: … It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could …
Prostaglandin D2
The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.
Investigational
WRR-99
Experimental
AGF-94
Investigational
MK-8777
MK-8777 is under investigation in clinical trial NCT00610649 (Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)).
Investigational
Neovastat
Neovastat is a naturally occurring anti-angiogenic compound, extracted from cartilage, with multiple anti-angiogenic mechanisms of action that provide broad therapeutic potential for a number of diseases. It is currently in international Phase III trials for renal cell carcinoma and non-small-cell lung cancer.
Investigational
TAFA-93
TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary...
Investigational
OSI-930
OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small...
Investigational
TAK-901
TAK-901 has been used in trials studying the treatment of Lymphoma, Myelofibrosis, Multiple Myeloma, Myeloid Metaplasia, and Advanced Solid Tumors, among others.
Investigational
SR-9009
SR-9009 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues .
Experimental
SR-9011
SR-9011 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues .
Experimental
Displaying drugs 951 - 975 of 1864 in total